Showing 4 results for Sarhangi
Negin Bozorgnejad, Hamid Reza Aghaei Meybodi, Mahdi Afshari, Negar Sarhangi, Mandana Hasanzad,
Volume 19, Issue 3 (2-2020)
Abstract
Background: Type 2 diabetes mellitus (T2DM) is the most common type of diabetes that was classically characterized by pancreatic β-cell dysfunction. Changes in circadian patterns is one of the reasons which can increase the occurrence of diabetes. Melatonin is one of the biological molecules which plays an important role in regulating the circadian clock and also an inhibitory effect on insulin secretion in β-cells. The aim of this study was to examine the association between MTNR1B (rs10830962) gene polymorphism and the risk of T2DM.
Methods: Genotyping was carried out in a total number of 208 subjects including 108 patients with T2DM and 100 normal controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) which is confirmed by Sanger sequencing method.
Results: The frequencies of CC, GC and GG among cases were 54.63%, 1.85% and 43.52% and in control subjects were 81%, 0% and 19% respectively (P<0.001). Frequency of G allele among diabetic patients was significantly higher than non-diabetics (OR=3.34, CI=2.10-5.36, P<0.001).
Conclusion: Our study showed that rs10830962 polymorphism of the MTNR1B gene can be directly associated with T2DM risk.
Anahita Fakhraei Nasab, Hamid Reza Aghaei Meybodi, Mahdi Afshari, Negar Sarhangi, Mandana Hasanzad,
Volume 19, Issue 4 (4-2020)
Abstract
Background: Type 2 diabetes Mellitus (T2DM) is a multifactorial, polygenic disease caused by impaired insulin secretion, insulin resistance and beta-cell dysfunction. Melatonin is a circadian rhythm regulator and any imbalance in its levels can be related to various metabolic disorders. Melatonin and the genetic variants of MTNR1B gene are reported to be associated with T2DM susceptibility. We investigated the association between rs4753426 variant in the MTNR1B gene and the risk of T2DM in group of Iranian patients.
Methods: In this case-control study108 T2DM and 100 normal individuals were recruited to genotyping by PCR- RFLP.
Results: It was observed a significant difference in CC, CT, and TT genotypes distribution between T2DM and control groups (P<0.001). Frequency of C allele among cases was significantly lower than controls (8.3% vs. 42.5% respectively, P<0.001) and C allele carriers had a 88% lower risk of developing T2DM than T carriers.
Conclusion: Our results showed that the rs4753426 variant of MTNR1B gene could reduce the risk of T2DM developing.
Mandana Hasanzad, Negar Sarhangi, Shekoufeh Nikfar, Bagher Larijani,
Volume 20, Issue 1 (25th Anniversary of the Foundation, Special Issue 2021)
Abstract
Background: Precision medicine is a new approach in the field of medical sciences that utilizes the genetic characteristics of each patient along with clinical information to guide decisions related to diagnosis and early treatment of diseases. The Personalized Medicine Research Center, as the only center approved by the Ministry of Health, is working on precision medicine context and producing the related knowledge.
Methods: In this systematic review, studies that are conducted at the personalized medicine research center with a precision medicine theme based on specific eligibility criteria and a designed search strategy in three databases PubMed, Scopus, and Web of Science (Wos) from December 2016 to December 2019 were retrieved.
Results: Finally, 18 studies focusing on different approaches of precision medicine in prediction, prevention through “omics” including genomics, transcriptomics, and proteomics were selected for further evaluation.
Finally, 18 studies focusing on precision medicine in non-communicable diseases (diabetes) and cancer (prostate and thyroid) were selected for further studies.
Conclusion: Since one of the important goals of precision medicine is prediction and prevention, the identified genetic changes can be used for early diagnosis in high-risk individuals. Actually, the initiative studies are needed to meet the goal of precision medicine.
Negar Sarhangi, Mandana Hasanzad, Fatemeh Rouhollah, Shekoufeh Nikfar, Farshad Sharifi, Negar Niknam,
Volume 25, Issue 2 (7-2025)
Abstract
Background: Pharmacogenomics (PGx), as a growing field of personalized medicine, aims to optimize the efficacy and safety of medications by studying the association between germline genetic variations and drug responses. The present cross-sectional study aims to evaluate the allele frequency of the NUDT15 genetic variant in the Iranian population to provide insights into personalized treatment decisions in the Iranian population.
Methods: A representative sample set of 1142 unrelated healthy Iranian individuals aged 18 and older genotyped using the Infinium Global Screening Array-24 BeadChip.
Results: We identified a pharmacogenetic variant with minor allele frequency (MAF) ≥1% among the present studied population which may explain the substantial variability in drug response phenotypes among different populations
Conclusion: The results of our study revealed significant genetic variation among Iranian populations that could significantly influence clinical decision-making. This study shows the frequency pattern of the effective variant of NUDT15 in determining the phenotype in Iranian population.
